
Please try another search
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic conditions with high unmet need in the United States. The company’s pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH023 which is phase 1 clinical trial used to treat multiple high value autoimmune indications; and HS1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Name | Age | Since | Title |
---|---|---|---|
Leonard L. Mazur | 80 | 2021 | Independent Director |
Vincent LoPriore | 57 | 2025 | Executive Chairman of the Board |
Lynne A. Bui | 54 | 2021 | Independent Director |
Sireesh Appajosyula | 49 | 2021 | CEO & Director |
Vaughn V. Smider | 56 | - | Member of Scientific Advisory Board |
James Gordon Liddy | - | 2025 | Director |
Gary S. Stetz | 62 | 2025 | Independent Director |
Clay Kahler | 61 | 2025 | Independent Director |
John Lambert | - | - | Member of Scientific Advisory Board |
Alan Bonder | - | - | Member of Scientific Advisory Board |
Sanam Parikh | 27 | 2024 | Independent Director |
Andreas Kremer | - | - | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review